Treats hypertension. ANDA 203023, held by Sun Pharm. Diltiazem Hydrochloride.
As of Nov 16, 2026, ANDA 203023 (Diltiazem Hydrochloride), held by Sun Pharm, was first approved by FDA on Jun 8, 2017, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Diltiazem hydrochloride extended-release capsules, USP are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medications. Diltiazem hydrochloride extended-release capsules, USP are indicated for the management of chronic stable angina and angina due to coronary artery spasm.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 8, 2017 | Original application | Approved | None posted |
| Diltiazem Hydrochloride120MG · capsule, extended release;oral | Diltiazem Hydrochloride | Discontinued |
| Diltiazem Hydrochloride180MG · capsule, extended release;oral | Diltiazem Hydrochloride | Discontinued |
| Diltiazem Hydrochloride240MG · capsule, extended release;oral | Diltiazem Hydrochloride | Discontinued |
| Diltiazem Hydrochloride300MG · capsule, extended release;oral | Diltiazem Hydrochloride | Discontinued |
| Diltiazem Hydrochloride360MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Jul 10, 2025 | Supplement 12Labeling · Standard review | Approved | None posted |
| May 8, 2023 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jun 8, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters